Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLOXIN vs EUTHROID-3
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
FDA-approved: Adjunctive therapy in euthyroid patients with primary hypercholesterolemia (elevated LDL) who have not responded to diet and other measures.,Off-label: Treatment of hypothyroidism (though not preferred); investigational use for reducing cardiovascular risk.
Hypothyroidism (thyroid hormone replacement therapy),Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
Terminal elimination half-life is approximately 1-2 hours in euthyroid patients; may be prolonged in hypothyroidism or hepatic impairment.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
Primarily hepatic; undergoes deiodination and conjugation to glucuronides and sulfates. Hepatic clearance involves CYP450 enzymes, with a half-life of approximately 12-24 hours.
Levothyroxine (T4) is metabolized to liothyronine (T3) via deiodination in peripheral tissues (liver, kidney, etc.). Liothyronine (T3) is metabolized via deiodination and conjugation (glucuronidation and sulfation) in the liver and kidneys. Hepatic enzymes involved include deiodinases (D1, D2) and UDP-glucuronosyltransferases (UGTs).
Primarily renal excretion of conjugated metabolites (70-80% of dose); biliary/fecal excretion accounts for 10-20%; less than 5% excreted unchanged.
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
Highly bound (>99%) to thyroxine-binding globulin (TBG), transthyretin, and albumin.
99.8% for L-T4 (thyroxine-binding globulin, transthyretin, albumin); 99.7% for L-T3 (same proteins, lower affinity).
Apparent volume of distribution is 0.10-0.20 L/kg, reflecting extensive tissue binding and distribution.
L-T4: 0.1-0.2 L/kg (mainly intravascular); L-T3: 0.4-0.6 L/kg (broader tissue distribution).
Oral bioavailability is 50-80%, reduced by food, bile acid sequestrants, and certain drugs.
Oral L-T4: 80-90% (fasting; reduced by food and malabsorption). Oral L-T3: 95-100% (well absorbed).
No dose adjustment required for renal impairment as drug is hepatically cleared.
No specific GFR-based dose adjustment required; monitor thyroid function in severe chronic kidney disease (GFR <30 m L/min/1.73 m²) as drug clearance may be reduced.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: reduce dose by 50-75% and monitor T4 closely.
No specific adjustment for Child-Pugh class A or B; use with caution in Child-Pugh C due to reduced hepatic conversion, monitor TSH.
Neonates: 10-15 mcg/kg/day orally. Infants: 5-10 mcg/kg/day. Children: 2-5 mcg/kg/day. Adjust based on T4 levels.
Not FDA-approved for children; adult dose not suitable. For hypothyroidism in children, use levothyroxine monotherapy at 25-50 mcg/day for ages 1-3 years, 50-100 mcg/day for ages 3-10 years, and 100-150 mcg/day for ages 10-16 years, adjusted per TSH.
Start at 25 mcg/day orally, titrate slowly (every 4-6 weeks) due to increased sensitivity and risk of cardiac adverse effects.
Start with lower dose: 25 mcg levothyroxine/7.5 mcg liothyronine (half tablet) orally once daily, titrate slowly every 4-6 weeks based on TSH, due to increased risk of cardiac adverse effects and altered metabolism.
None specified in FDA labeling.
None
Cardiac toxicity: Increased risk of arrhythmias, angina, and myocardial infarction, especially in patients with pre-existing cardiovascular disease.,Hyperthyroidism: Can induce thyrotoxicosis if dose is too high or in patients with iodine deficiency.,Drug interactions: Enhances effect of oral anticoagulants (reduce warfarin dose); decreases effect of antidiabetic medications; alters response to digitalis.,Use in pregnancy: Category X – contraindicated due to teratogenic effects.
Cardiac toxicity (e.g., arrhythmias, angina, myocardial infarction) due to excessive thyroid hormone levels,Thyrotoxic crisis (thyroid storm) if overdosed,Adrenal insufficiency: may precipitate acute adrenal crisis in patients with adrenal insufficiency,Delayed bone maturation in children if overtreated,Interactions with anticoagulants (increased INR), oral antidiabetic agents (hyperglycemia), and catecholamines (sympathomimetic effects)
Absolute: Euthyroid patients with pre-existing cardiovascular disease (e.g., recent MI, unstable angina, significant arrhythmias).,Absolute: Thyrotoxicosis or iodine deficiency.,Absolute: Pregnancy (Category X).,Relative: Renal or hepatic impairment; concomitant use of anticoagulants (requires close monitoring).
Untreated adrenal insufficiency,Thyrotoxicosis (any etiology),Acute myocardial infarction (recent),Hypersensitivity to any component
High-fiber foods (e.g., bran, whole grains) may reduce absorption; take levothyroxine separately. Soy-containing products (e.g., tofu, soy milk) and grapefruit juice can alter absorption. Consume these at least 4 hours apart from dosing. Avoid taking with walnuts, cottonseed meal, or concentrated iron-rich foods.
Take on an empty stomach with water. Avoid concurrent intake with high-fiber foods, walnuts, soybean flour, cottonseed meal, or calcium/iron supplements within 4 hours of dosing as they may reduce absorption.
CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of congenital defects; second and third trimester exposure may impair fetal thyroid function and development. Risk cannot be excluded.
Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic risk from exogenous thyroid hormone. Fetal thyroid function develops at 10-12 weeks; prior to that, fetus depends on maternal T4. Overdose may cause fetal thyrotoxicosis. First trimester: maternal hypothyroidism increases risk of miscarriage and neurodevelopmental deficits. Second/third trimester: overtreatment may cause fetal tachycardia and growth restriction. Postpartum: adjust dose to prevent maternal hypothyroidism.
Excretion into human milk is unknown. Due to potential for serious adverse effects in nursing infants, including interference with thyroid function, breastfeeding is contraindicated. M/P ratio not determined.
Excreted in human milk in low amounts. T3 and T4 are endogenous hormones; exogenous administration results in minimal transfer. M/P ratio: not established for Euthroid-3, but for levothyroxine, M/P ratio ~0.001. Considered compatible with breastfeeding when used at recommended doses. Monitor infant for thyroid suppression (rare at maternal therapeutic doses).
Pregnancy increases thyroid hormone requirements. Dextrothyroxine is not recommended due to lack of safety data. If used, dose may need increase based on TSH monitoring. Hyperthyroid effects may necessitate dose reduction. Not a standard therapy; levothyroxine is preferred.
Pregnancy increases T4 clearance due to increased TBG and placental deiodination. Dose may need to increase by 20-50% as early as 4-6 weeks gestation. Start with increased dose of 30-50% of prepregnancy dose. Adjust based on TSH every 4-6 weeks. Typical dose increase: 30-50% above baseline. Liothyronine component may require adjustment; monitor free T3 if using T3 therapy. Postpartum: reduce dose back to prepregnancy level.
CHOLOXIN (sodium levothyroxine) is a synthetic T4 thyroid hormone. Monitor TSH levels 6-8 weeks after dose changes; target TSH 0.5-2.5 m IU/L for most adults. Administer on empty stomach, 30-60 minutes before breakfast, with water. Avoid concurrent calcium, iron, or antacids within 4 hours. Dose adjustments needed in pregnancy, with T4 dose increase by 30-50% typically. Check for drug interactions with amiodarone, oral contraceptives, and tyrosine kinase inhibitors.
Euthroid-3 is a combination of liothyronine (T3) and levothyroxine (T4) in a fixed 1:4 ratio. Monitor TSH, free T4, and free T3 levels to avoid iatrogenic hyperthyroidism. Adjust dose cautiously in elderly or cardiac patients. Use with caution in adrenal insufficiency as thyroid replacement can precipitate adrenal crisis.
Take levothyroxine on an empty stomach, at least 30-60 minutes before breakfast.,Take with a full glass of water, not with other beverages.,Do not take within 4 hours of calcium or iron supplements, antacids, or sucralfate.,Consistency is key: take the same brand and dose daily; do not switch brands without consulting your provider.,Report symptoms of hyperthyroidism (palpitations, anxiety, weight loss) or hypothyroidism (fatigue, cold intolerance, constipation) promptly.,Do not stop or change dose without talking to your doctor; lab monitoring is required.,If you miss a dose, take it as soon as remembered, but skip if near next dose; do not double.,Inform all healthcare providers you are taking this medication, especially before surgery or starting new meds.
Take exactly as prescribed, typically once daily on an empty stomach 30-60 minutes before breakfast.,Do not switch between different thyroid hormone products without consulting your doctor.,Report symptoms of hyperthyroidism (rapid heartbeat, chest pain, heat intolerance, excessive sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Inform all healthcare providers you are taking this medication.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLOXIN vs EUTHROID-3, answered by our medical review team.
CHOLOXIN is a Thyroid Hormone Analog that works by Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.. EUTHROID-3 is a Thyroid Hormone Replacement that works by EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLOXIN and EUTHROID-3 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLOXIN is: 50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.. The standard adult dose of EUTHROID-3 is: Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLOXIN and EUTHROID-3 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLOXIN is classified as Category C. CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of . EUTHROID-3 is classified as Category C. Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.